Skip to content

LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study

A Lerner, Marc Gelkopf, Igor Oyffe, Boris Finkel, S Katz, Mircea Sigal, Abraham Weizman

International Clinical Psychopharmacology 2000 DOI: 10.1097/00004850-200015010-00005 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Open-label pilot study Peer reviewed
Sample size 8
Population Patients with LSD-induced hallucinogen persisting perception disorder (HPPD)
Intervention Clonidine
Dose 0.025 mg three times a day
Duration 2 months
Measures Clinical Global Impression Scale (CGI), self-report scale on severity of symptoms (graded 0-5)
Topics LSD
Keywords Clonidine Hallucinogen Psychopathology Clinical global impression Anesthesia Open label
Citations 39
Key points Clonidine reduced symptom severity from marked to mild in patients with HPPD, as measured by the Clinical Global Impression Scale and a self-report scale.

Abstract

A pilot open study was conducted in order to evaluate the efficacy of clonidine in the treatment of LSD-induced hallucinogen persisting perception disorder (HPPD). Eight patients fulfilled entrance criteria. All complained of HPPD for at least 3 months and were drug free at least 3 months. They received fixed low doses of clonidine, 0.025 mg, three times a day for 2 months. They were evaluated by the Clinical Global Impression Scale (CGI) and a self-report scale on the severity of symptoms (graded 0-5). Patients scored an average of 5.25 (SD = 0.46) on the CGI and 4 on the self-report scale at baseline, indicating marked psychopathology. One patient dropped out at week 3 and a second patient dropped out at week 5. Of the six patients remaining at the end of 2 months, the average CGI score was 2.5 (SD = 0.55) and the self-report scale score was 2, indicating mild symptomatology. LSD-related flashbacks associated with excessive sympathetic nervous activity may be alleviated with clonidine in some patients.